Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome

Annals of the New York Academy of Sciences

Volumn 966, Issue , 2002, Pages 415-424

  Chapman, Joab ^a   Shoenfeld, Yehuda ^b,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Behavior; Chorea; Dementia; Epilepsy; Neurology

Indexed keywords

BETA2 GLYCOPROTEIN 1; CYTOKINE; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY;

AMNESIA; ANTIPHOSPHOLIPID SYNDROME; BEHAVIOR; CHOREA; CLINICAL FEATURE; COGNITION; CONFERENCE PAPER; DEMENTIA; DISEASE ASSOCIATION; EPILEPSY; HUMAN; HYPERACTIVITY; IMMUNIZATION; LEARNING DISORDER; MIGRAINE; NEUROENDOCRINE SYSTEM; PATHOGENESIS; STROKE;

ANIMALIA;

EID: 0036300786     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04242.x     Document Type: Conference Paper

References (114)

1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrom
2. The spectrum of neurologic disease associated with antiphospholipid antibodies: Lupus anticoagulants and anticardiolipin antibodies
3. Central nervous system involvement in antiphospholipid syndrome
4. Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome
5. Antiphospholipid syndrome: Insights from animal models
6. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome
7. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia
8. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: Prevalence and clinical significance
9. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies
10. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia
11. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome
12. Antiphospholipid syndrome: Patterns of life-threatening and severe recurrent vascular complications
13. Antiphospholipid antibodies and cerebral ischemia in young people
14. Antiphospholipid antibodies in systemic lupus erythematosus: Clinical and laboratory associations in 111 patients
15. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset
16. Thrombosis in patients with SLE and antiphospholipid syndrome
17. Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: Clinical and laboratory associations
18. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death
19. The frequency of phospholipid antibodies in an unselected stroke population
20. Anticardiolipin antibodies and their associations with cerebrovascular risk factors
21. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke
22. The association of antiphospholipid antibodies with ischaemic stroke and myocardial infarction in young and their correlation: A preliminary study
23. Cerebrovascular ischemic events with high positive anticardiolipin antibodies
24. Anticardiolipin antibody and stroke: Possible relation of valvular heart disease and embolic events
25. Stroke in systemic lupus erythematosus
26. Detection of cerebral microembolic signals by transcranial Doppler may be a useful part of the equation in determining stroke risk in patients with antiphospholipid antibody syndrome
27. Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?
28. Cerebral microemboli in patients with antiphospholipid syndrome
29. Lessons from experimental APS models
30. Anti-phospholipid syndrome: From patient's bedside to experimental animal models and back to the patient's bedside
31. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event
32. Antiphospholipid syndrome in systemic lupus erythematosus - Immunomorphological study of the central nervous system; case report
33. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus
34. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome
35. Systemic lupus erythematosus complicated by thrombotic microangiopathy
36. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies
37. Reactivity patterns of antiphospholipid antibodies and endothelial cells: Effect of antiendothelial antibodies on cell migration
38. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis
39. Higher cortical dysfunction, antiphospholipid antibodies and neuroradiological examinations in systemic lupus erythematosus
40. 123I]iodoamphetamine (IMP) in the cases of antiphospholipid syndrome
41. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome
42. Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome
43. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus
44. The management of throbosis in the antiphospholipid-antibody syndrome
45. Thrombolysis for acute ischemic stroke in the primary antiphospholipid syndrome
46. Central nervous system involvement in pregnant rabbits with experimental model of antiphospholipid syndrome
47. Autoimmune MRL-1 pr/1pr mice are an animal model for the secondary antiphospholipid syndrome
48. Induction of experimental antiphospholipid syndrome in PL/J mice following immunization with beta 2 GPI
49. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies: A mouse model
50. The lupus anticoagulant and dementia in non-SLE patients
51. Dementia in the primary antiphospholipid syndrome is associated with increased age, high levels of antiphospholipid antibodies and diffuse brain pathology
52. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus
53. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: Association with antiphospholipid antibodies
54. Primary antiphospholipid syndrome and cerebral atrophy: A rare association?
55. Primary antiphospholipid syndrome: Functional outcome after 10 years
56. Dementia and antiphospholipid antibodies
57. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells
58. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system
59. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain
60. Anti-beta 2-glycoprotein I antibodies bind to central nervous system
61. Sneddon syndrome: New clinical and immunological data
62. Cognitive and neurologic deficits in the MRL/lpr mouse: A clinicopathologic study
63. Hyperactivity in a mouse model of the antiphospholipid syndrome
64. Cognitive and behavioral deficits develop late in a mouse model of the antiphospholipid syndrome (APS)
65. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I
66. Passive transfer of cognitive deficits by intrathecal injection of antiphospholipid IgG
67. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood
68. Valvular deposition of antiphospholipid antibedies in the antiphospholipid syndrome: A clue to the origin of the disease
69. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood
70. Chorea in systemic lupus erythematosus and "lupus-like" disease: Association with antiphospholipid antibodies
71. Chorea and systemic lupus erythematosus with circulating anticoagulant. 3 Cases
72. Chorea in the antiphospholipid syndrome: Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature
73. Chorea in systemic lupus erythematosus: Association with antiphospholipid antibodies
74. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood
75. Alternating hemichorea in primary antiphospholipid syndrome: Evidence for contralateral striatal hypermetabolism
76. Chorea in juvenile primary antiphospholipid syndrome. Reversible decreased circulation in the basal ganglia visualised by single photon emission computed tomography
77. Reversible chorea in primary antiphospholipid syndrome
78. Diagnostic and therapeutic problems in two patients with antiphospholipid antibodies, heart valve lesions, and transient ischaemic attacks
79. Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: A case report
80. Anticardiolipin antibodies in acute rheumatic fever
81. Lupus anticoagulant, antiphospholipid antibodies and migraine
82. Anticardiolipin antibodies and their association with the brain
83. Migraine in patients with stroke and antiphospholipid antibodies
84. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders
85. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus
86. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus
87. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes
88. Acute optic neuropathy and transverse myelopathy in patients with antiphospholipid antibody syndrome: Favorable outcome after treatment with anticoagulants and glucocorticoids
89. Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus
90. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature
91. Lupus anticoagulant: Correlation with magnetic resonance imaging of brain lesions
92. Patients with antiphospholipid antibodies: CT and MR findings of the brain
93. Systemic autoimmune features and multiple sclerosis: A 5-year follow-up study
94. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: Do they represent a new nosological entity?
95. Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases
96. Induction of anti-phospholipid syndrome by passive transfer of anti-cardiolipin antibodies
97. Lessons from experimental anti-phospholipid syndrome
98. Role of IL-3 in the antiphospholipid syndrome
99. Mechanisms of action of antiphospholipid antibodies in the antiphospholipid syndrome
100. Interleukin-3 and pregnancy loss in antiphospholipid syndrome
101. The putative role of cytokines in the induction of primary anti-phospholipid syndrome in mice
102. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3
103. Aspirin modulates interleukin-3 production: Additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome
104. Aspirin-interleukin-3 inter-relationships in patients with anti-phospholipid syndrome
105. Treatment of systemic lupus erythematosus and antiphospholipid syndrome: From experimental models to patients' bedside
106. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression
107. Interleukin-3 and human trophoblast: in vitro explanation for the effect of interleukin in patients with antiphospholipid syndrome
108. Macrophage/microglia-mediated primary demyelination and motor disease induced by the central nervous systerm production of interleukin-3 in transgenic mice
109. In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy
110. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion
111. Hypopituitarism and antiphospholipid syndrome
112. Adrenal hemorrhage in patients with primary antiphospholipid syndrome: Imaging findings
113. Bilateral adrenal hemorrhage with adrenal insufficiency in the framework of primary antiphospholipid antibody syndrome
114. Childhood adrenal insufficiency, chorea, and antiphospholipid antibodies